Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window Joint outcome table analysis of the ECASS 3 trial

Jeffrey L. Saver, Jeffrey Gornbein, James Grotta, David Liebeskind, Helmi Lutsep, Lee Schwamm, Phillip Scott, Sidney Starkman

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background and Purpose - Measures of a therapy's effect size are important guides to clinicians, patients, and policy-makers on treatment decisions in clinical practice. The ECASS 3 trial demonstrated a statistically significant benefit of intravenous tissue plasminogen activator for acute cerebral ischemia in the 3- to 4.5-hour window, but an effect size estimate incorporating benefit and harm across all levels of poststroke disability has not previously been derived. Methods - Joint outcome table specification was used to derive number needed to treat to benefit (NNTB) and number needed to treat to harm (NNTH) values summarizing treatment impact over the entire outcome range on the modified Rankin scale of global disability, including both expert-dependent and expert-independent (algorithmic and repeated random sampling) array generation. Results - For the full 7-category modified Rankin scale, algorithmic analysis demonstrated that the NNTB for 1 additional patient to have a better outcome by ≥ 1 grades than with placebo must lie between 4.0 and 13.0. In bootstrap simulations, the mean NNTB was 7.1. Expert joint outcome table analyses indicated that the NNTB for improved final outcome was 6.1 (95% CI, 5.6-6.7) and the NNTH 37.5 (95% CI, 34.6-40.5). Benefit per 100 patients treated was 16.3 and harm per 100 was 2.7. The likelihood of help to harm ratio was 6.0. Conclusions - Treatment with tissue plasminogen activator in the 3- to 4.5-hour window confers benefit on approximately half as many patients as treatment

Original languageEnglish (US)
Pages (from-to)2433-2437
Number of pages5
JournalStroke
Volume40
Issue number7
DOIs
StatePublished - Jul 1 2009

Fingerprint

Numbers Needed To Treat
Tissue Plasminogen Activator
Therapeutics
Brain Ischemia
Administrative Personnel
Placebos

Keywords

  • Cerebral infarction
  • Clinical trial
  • Fibrinolysis
  • Ischemic stroke
  • Thrombolysis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window Joint outcome table analysis of the ECASS 3 trial. / Saver, Jeffrey L.; Gornbein, Jeffrey; Grotta, James; Liebeskind, David; Lutsep, Helmi; Schwamm, Lee; Scott, Phillip; Starkman, Sidney.

In: Stroke, Vol. 40, No. 7, 01.07.2009, p. 2433-2437.

Research output: Contribution to journalArticle

Saver, Jeffrey L. ; Gornbein, Jeffrey ; Grotta, James ; Liebeskind, David ; Lutsep, Helmi ; Schwamm, Lee ; Scott, Phillip ; Starkman, Sidney. / Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window Joint outcome table analysis of the ECASS 3 trial. In: Stroke. 2009 ; Vol. 40, No. 7. pp. 2433-2437.
@article{57af0c0fbef649a3a64b981c576906d3,
title = "Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window Joint outcome table analysis of the ECASS 3 trial",
abstract = "Background and Purpose - Measures of a therapy's effect size are important guides to clinicians, patients, and policy-makers on treatment decisions in clinical practice. The ECASS 3 trial demonstrated a statistically significant benefit of intravenous tissue plasminogen activator for acute cerebral ischemia in the 3- to 4.5-hour window, but an effect size estimate incorporating benefit and harm across all levels of poststroke disability has not previously been derived. Methods - Joint outcome table specification was used to derive number needed to treat to benefit (NNTB) and number needed to treat to harm (NNTH) values summarizing treatment impact over the entire outcome range on the modified Rankin scale of global disability, including both expert-dependent and expert-independent (algorithmic and repeated random sampling) array generation. Results - For the full 7-category modified Rankin scale, algorithmic analysis demonstrated that the NNTB for 1 additional patient to have a better outcome by ≥ 1 grades than with placebo must lie between 4.0 and 13.0. In bootstrap simulations, the mean NNTB was 7.1. Expert joint outcome table analyses indicated that the NNTB for improved final outcome was 6.1 (95{\%} CI, 5.6-6.7) and the NNTH 37.5 (95{\%} CI, 34.6-40.5). Benefit per 100 patients treated was 16.3 and harm per 100 was 2.7. The likelihood of help to harm ratio was 6.0. Conclusions - Treatment with tissue plasminogen activator in the 3- to 4.5-hour window confers benefit on approximately half as many patients as treatment",
keywords = "Cerebral infarction, Clinical trial, Fibrinolysis, Ischemic stroke, Thrombolysis",
author = "Saver, {Jeffrey L.} and Jeffrey Gornbein and James Grotta and David Liebeskind and Helmi Lutsep and Lee Schwamm and Phillip Scott and Sidney Starkman",
year = "2009",
month = "7",
day = "1",
doi = "10.1161/STROKEAHA.108.543561",
language = "English (US)",
volume = "40",
pages = "2433--2437",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window Joint outcome table analysis of the ECASS 3 trial

AU - Saver, Jeffrey L.

AU - Gornbein, Jeffrey

AU - Grotta, James

AU - Liebeskind, David

AU - Lutsep, Helmi

AU - Schwamm, Lee

AU - Scott, Phillip

AU - Starkman, Sidney

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Background and Purpose - Measures of a therapy's effect size are important guides to clinicians, patients, and policy-makers on treatment decisions in clinical practice. The ECASS 3 trial demonstrated a statistically significant benefit of intravenous tissue plasminogen activator for acute cerebral ischemia in the 3- to 4.5-hour window, but an effect size estimate incorporating benefit and harm across all levels of poststroke disability has not previously been derived. Methods - Joint outcome table specification was used to derive number needed to treat to benefit (NNTB) and number needed to treat to harm (NNTH) values summarizing treatment impact over the entire outcome range on the modified Rankin scale of global disability, including both expert-dependent and expert-independent (algorithmic and repeated random sampling) array generation. Results - For the full 7-category modified Rankin scale, algorithmic analysis demonstrated that the NNTB for 1 additional patient to have a better outcome by ≥ 1 grades than with placebo must lie between 4.0 and 13.0. In bootstrap simulations, the mean NNTB was 7.1. Expert joint outcome table analyses indicated that the NNTB for improved final outcome was 6.1 (95% CI, 5.6-6.7) and the NNTH 37.5 (95% CI, 34.6-40.5). Benefit per 100 patients treated was 16.3 and harm per 100 was 2.7. The likelihood of help to harm ratio was 6.0. Conclusions - Treatment with tissue plasminogen activator in the 3- to 4.5-hour window confers benefit on approximately half as many patients as treatment

AB - Background and Purpose - Measures of a therapy's effect size are important guides to clinicians, patients, and policy-makers on treatment decisions in clinical practice. The ECASS 3 trial demonstrated a statistically significant benefit of intravenous tissue plasminogen activator for acute cerebral ischemia in the 3- to 4.5-hour window, but an effect size estimate incorporating benefit and harm across all levels of poststroke disability has not previously been derived. Methods - Joint outcome table specification was used to derive number needed to treat to benefit (NNTB) and number needed to treat to harm (NNTH) values summarizing treatment impact over the entire outcome range on the modified Rankin scale of global disability, including both expert-dependent and expert-independent (algorithmic and repeated random sampling) array generation. Results - For the full 7-category modified Rankin scale, algorithmic analysis demonstrated that the NNTB for 1 additional patient to have a better outcome by ≥ 1 grades than with placebo must lie between 4.0 and 13.0. In bootstrap simulations, the mean NNTB was 7.1. Expert joint outcome table analyses indicated that the NNTB for improved final outcome was 6.1 (95% CI, 5.6-6.7) and the NNTH 37.5 (95% CI, 34.6-40.5). Benefit per 100 patients treated was 16.3 and harm per 100 was 2.7. The likelihood of help to harm ratio was 6.0. Conclusions - Treatment with tissue plasminogen activator in the 3- to 4.5-hour window confers benefit on approximately half as many patients as treatment

KW - Cerebral infarction

KW - Clinical trial

KW - Fibrinolysis

KW - Ischemic stroke

KW - Thrombolysis

UR - http://www.scopus.com/inward/record.url?scp=67650084702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650084702&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.108.543561

DO - 10.1161/STROKEAHA.108.543561

M3 - Article

VL - 40

SP - 2433

EP - 2437

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 7

ER -